SOURCE: UltraSPECT Inc.

UltraSPECT Inc.

May 02, 2013 08:53 ET

UltraSPECT Partners With PharmaLogic to Offer Dose Reduction Solution

Hospitals and Their Patients to Benefit From Reduced Dose and Faster Exams

AUBURNDALE, MA--(Marketwired - May 2, 2013) - UltraSPECT, a leading provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces their distribution agreement with PharmaLogic for the sale of UltraSPECT's Cardiac and Bone imaging applications. The agreement will enable PharmaLogic to provide its hospitals and imaging centers with access to UltraSPECT's Xpress line of products for significantly lower radiation dose with no diminished image quality.

"Our close partnership with UltraSPECT enhances PharmaLogic's product and service offering by allowing us to deliver enhanced solutions to our nuclear medicine customers, and to specifically address the industry's recently launched Image Wisely™ campaign," said Steve Chilinski, president and CEO of PharmaLogic. "UltraSPECT's proprietary Wide-Beam Reconstruction technology enables our customers to achieve significant radiation dose reduction combined with greater patient comfort and higher throughput capacity. Even better, this technology can be easily implemented by retrofitting our customers' existing facilities without the cost of new imaging camera systems. We are already seeing significant interest in this innovative solution from our customers."

Through the use of UltraSPECT's innovative Wide-Beam Reconstruction (WBR™) technology, the products in the company's growing portfolio of solutions can provide two unique advantages. They significantly reduce the standard radiopharmaceutical dose requirements for cardiac and bone nuclear medicine imaging exams and/or cut the imaging procedure time in half while maintaining the image quality the facility is accustomed to, and many times even enhancing the image resolution. The company's Xpress3.Cardiac™ solution provides optimal benefits -- enabling nuclear exams to be performed with both 50 percent reduction in both dose and procedure time.

Both patients and technologists benefit from these improvements. With shorter exam times, patient comfort is increased with reduced risk of artifacts from patient movement. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many UltraSPECT users, the WBR technology results in higher patient throughput for enhanced equipment utilization, higher revenues and greater patient satisfaction and referrals.

"Our mission is to help more hospitals and imaging centers to comply with the reduced-dose guidelines recommended by the American Society of Nuclear Cardiology to be effective January 1, 2014. Through our partnership with PharmaLogic, we will be able to supplement our distribution, therefore providing more facilities with the low dose benefit of UltraSPECT's innovative technologies," said Yossi Srour, president and CEO, UltraSPECT. "We anticipate great demand for the UltraSPECT product line from PharmaLogic customers and look forward to the opportunity to work with other radiopharmaceutical providers in order to help bring UltraSPECT's invaluable products to more healthcare facilities and their patients."

UltraSPECT's growing product line, utilizing the groundbreaking WBR technology, is compatible with most major manufacturers' NM systems as well as all clinical software packages. The technology is a far more cost effective dose reduction alternative to complete replacement cameras. UltraSPECT's Xpress products for achieving reduced dose and scan time are already successfully utilized in hundreds locations throughout the U.S. and Europe.

About UltraSPECT
UltraSPECT Inc. is a leading provider of image reconstruction products dedicated to enhancing the performance of existing nuclear medicine gamma cameras and PET scanners. Based on proprietary, innovative reconstruction algorithms, UltraSPECT's Wide-Beam Reconstruction (WBR™) solutions lower radiation dose, shorten acquisition times, and increase image resolution. Xpress.Cardiac™ enables rest/stress study acquisition with either half the radiopharmaceutical dose or in half the scan time compared to conventional acquisition techniques. Xpress3.Cardiac™ offers simultaneous reduced-dose and reduced-time imaging, supporting increased patient safety and comfort. For more information visit: www.ultraspect.com or contact UltraSPECT Inc. at 1-888-WBR-SCAN (1-888-927-7226).

About PharmaLogic:
PharmaLogic is a leading provider of nuclear medicine radiopharmacy services and solutions for use in diagnostic imaging and radiopharmaceutical therapies.

PharmaLogic prepares and delivers patient-specific doses ready to administer with exceptional on-time delivery performance despite unpredictable environmental elements or other outside factors. The doses are compounded by licensed Nuclear Pharmacists and personally delivered to its customers by dedicated customer service assistants. For more information, visit www.pharmalogic.info.

Contact Information